Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • We spotlight the promising preliminary findings reported by Goldsmith et¬†al. of a phase 1 first-in-child study¬†showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.1.

publication date

  • June 2023